Alexion gambles on an early-stage drug for rare diseases, bagging Apple Tree-backed Syntimmune in $1.2B buyout
Alexion Pharmaceuticals is adding a clinical-stage asset to the pipeline, buying Syntimmune for $400 million upfront with another $800 million on the table for milestones.
The big prize here is the antibody SYNT001, which is being studied for rare IgG-mediated diseases. The lead program is a Phase Ib/IIa study that is examining its efficacy in warm autoimmune hemolytic anemia (WAIHA) and in patients with pemphigus vulgaris (PV) or pemphigus foliaceus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.